 Antiretroviral ARV treatment guidelines currently recommend ARV regimens containing a Nucleostide Reverse Transcriptase Inhibitors NtRTIs based backbone with a Non Nucleoside Reverse Transcriptase Inhibitor NNRTI or ritonavir boosted Protease Inhibitor PIr.1 However, significant toxicity has been associated with NtRTIs and PIr containing regimens. NtRTIs can cause lipoatrophy, lipid elevations, renal toxicity, neuropathy and lactic acidosis.1 These toxicities have required clinicians and HIV-infected individuals to use alternative ARV regimens that do not use NtRTIs. PIs are known to cause gastrointestinal side effects, dyslipidemia, and fat maldistribution lipodystrophy.1 The DHHS HIV treatment guidelines recommend that PIs should be given with a low dose of ritonavir RTV. RTV is a PI that has an inhibitory effect on cytochrome P-450 3A4 isoenzyme which metabolizes most PIs. The addition of RTV serves as a pharmacokinetic booster by increasing PI drug concentrations.1 However, RTV is known to increase PI side effects, elevate lipid levels and has significant drug-drug interactions with many medications given to HIV individuals.1 These RTV drug interactions can complicate the medical care of an HIV-infected individual. 